Together, the three companies supply about 90% of insulin used in the United States.
, at $35 per month. The company will also lower prices on its short-acting insulin, Apidra, by 70%.
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," Olivier Bogillot, head of U.S. General Medicines at Sanofi, said in a news release. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.
Sanofi joins both Eli Lilly and Novo Nordisk, which made similar price cut announcements earlier this month, as well as Medicare, which has begun limiting insulin costs for seniors."It seemed like only a matter of time" before Sanofi also made changes, Stacie Dusetzina, a health policy professor at Vanderbilt University Medical Center in Nashville, Tenn.
Insulin prices have been much higher in the United States than in other countries, where 8.4 million Americans rely on the medication, according to
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo NordiskThe French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.
Read more »
Sanofi is the latest insulin maker to announce price capSanofi joins Eli Lilly and Novo Nordisk to cap insulin prices. President Joe Biden still wants Congress to enact limits. MORE ⬇️
Read more »
Sanofi to Cut US Price of Its Most-Prescribed Insulin by 78%Sanofi said on Thursday it will cut US list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly.
Read more »
Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%French drugmaker Sanofi SA said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big diabetes drugmakers facing pressure over high costs.
Read more »
Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Read more »
Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Read more »